Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03647098
Recruitment Status : Enrolling by invitation
First Posted : August 27, 2018
Last Update Posted : August 28, 2018
Sponsor:
Information provided by (Responsible Party):
Yongchang Zhang, MD, Hunan Province Tumor Hospital

Brief Summary:
this study is to analyze the survival condition of different groups about non-small cell lung cancer patients with KRAS mutations。The groups are made according to the treatment regime,brain metastases and gene mutation

Condition or disease Intervention/treatment
KRAS Gene Mutation Advanced Non-small Cell Lung Cancer Genetic: kras

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1200 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer Based on NGS Test Results in Hunan Province China
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : June 1, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Cohorts 1
Treatment plan
Cohorts 2
brain metastases
Cohorts 3
Concomitant KRAS mutation
Genetic: kras
the gene mutation




Primary Outcome Measures :
  1. OS [ Time Frame: Approximately 1 years ]
    Overall survival


Secondary Outcome Measures :
  1. PFS [ Time Frame: Approximately 1 years ]
    Progression free survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
the people who are advanced non-small cell lung cancer with KRAS mutation by NGS in Hunan province China
Criteria

Inclusion Criteria:

  • advanced non-small cell lung cancer stage IIIB/IV
  • KRAS mutation
  • non-squmous

Exclusion Criteria:

  • squmous non-small cell lung cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03647098


Locations
Layout table for location information
China, Hunan
Hunan Provincal Tumor Hospital
Changsha, Hunan, China, 410013
Sponsors and Collaborators
Hunan Province Tumor Hospital

Layout table for additonal information
Responsible Party: Yongchang Zhang, MD, professor, Hunan Province Tumor Hospital
ClinicalTrials.gov Identifier: NCT03647098     History of Changes
Other Study ID Numbers: KILLER
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: August 28, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms